Guardant Health Inc., a precision oncology company, has announced the launch of the Guardant Hereditary Cancer test. This germline test is designed to identify genetic variants associated with cancer risk, aiding healthcare providers in delivering optimal patient care. The test can be ordered for patients with a personal or family history of hereditary cancer to guide treatment decisions, assess risk for secondary cancers, and potentially identify other at-risk family members. Requiring only a blood draw, the test results are available within two to three weeks. The Guardant Hereditary Cancer test analyzes 82 genes linked to increased risk for over 12 tumor types, including breast, colorectal, and prostate cancers.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.